Extending Aromatase-Inhibitor Adjuvant Therapy to 10 Years

Extending Aromatase-Inhibitor Adjuvant Therapy to 10 Years

BACKGROUND Treatment with an aromatase inhibitor for 5 years as up-front monotherapy or after tamoxifen therapy is the treatment of choice for hormone-receptor-positive early breast cancer in postmenopausal women. Extending treatment with an aromatase inhibitor to 10 years may further reduce the ris...

Full description

Bibliographic Details
Main Authors: Goss, Paul E., Ingle, James N., Pritchard, Kathleen I., Robert, Nicholas J., Muss, Hyman, Gralow, Julie, Gelmon, Karen, Whelan, Tim, Strasser-Weippl, Kathrin, Rubin, Sheldon, Sturtz, Keren, Wolff, Antonio C., Winer, Eric, Hudis, Clifford, Stopeck, Alison, Beck, J. Thaddeus, Kaur, Judith S., Whelan, Kate, Tu, Dongsheng, Parulekar, Wendy R.
Other Authors: Univ Arizona
Language:en
Published: MASSACHUSETTS MEDICAL SOC 2016
Online Access:http://hdl.handle.net/10150/621478
http://arizona.openrepository.com/arizona/handle/10150/621478

Internet

http://hdl.handle.net/10150/621478
http://arizona.openrepository.com/arizona/handle/10150/621478

Similar Items